| Titre : |
Novel Therapeutics in Autism Spectrum Disorders |
| Type de document : |
Texte imprimé et/ou numérique |
| Auteurs : |
Evdokia ANAGNOSTOU, Auteur ; Caitlyn MCKEEVER, Auteur ; Azadeh KUSHKI, Auteur |
| Année de publication : |
2013 |
| Importance : |
p.103-109 |
| Langues : |
Anglais (eng) |
| Index. décimale : |
SCI-D SCI-D - Neurosciences |
| Résumé : |
Although ASD (autistic spectrum disorder) has seen significant gains in the area of therapeutics over the last 2 decades, it has also been characterized by the inability to successfully treat core symptom domains. In this chapter, we discuss challenges faced in this area, including limitations related to measuring outcomes, ability to capture the heterogeneity of ASD adequately, and lack of data in the rapidly growing adult population who have ASD. We then discuss novel approaches to therapeutics research in ASD, which include translating emerging findings from genomics, neuropathology and animal models into treatment, and discuss potential novel molecular targets in this area, such as glutamate/GABA related pathways, oxytocin/vasopressin, and immune modulation. The need to combine such treatments with evolving psychoeducational interventions is highlighted as it has the potential to modify the developmental trajectories of individuals with ASD. |
| Permalink : |
https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=189 |
Novel Therapeutics in Autism Spectrum Disorders [Texte imprimé et/ou numérique] / Evdokia ANAGNOSTOU, Auteur ; Caitlyn MCKEEVER, Auteur ; Azadeh KUSHKI, Auteur . - 2013 . - p.103-109. Langues : Anglais ( eng)
| Index. décimale : |
SCI-D SCI-D - Neurosciences |
| Résumé : |
Although ASD (autistic spectrum disorder) has seen significant gains in the area of therapeutics over the last 2 decades, it has also been characterized by the inability to successfully treat core symptom domains. In this chapter, we discuss challenges faced in this area, including limitations related to measuring outcomes, ability to capture the heterogeneity of ASD adequately, and lack of data in the rapidly growing adult population who have ASD. We then discuss novel approaches to therapeutics research in ASD, which include translating emerging findings from genomics, neuropathology and animal models into treatment, and discuss potential novel molecular targets in this area, such as glutamate/GABA related pathways, oxytocin/vasopressin, and immune modulation. The need to combine such treatments with evolving psychoeducational interventions is highlighted as it has the potential to modify the developmental trajectories of individuals with ASD. |
| Permalink : |
https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=189 |
|
Novel Therapeutics in Autism Spectrum Disorders